Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.

Sardella G, Calcagno S, Mancone M, Palmirotta R, Lucisano L, Canali E, Stio RE, Pennacchi M, Di Roma A, Benedetti G, Guadagni F, Biondi-Zoccai G, Fedele F.

Circ Cardiovasc Interv. 2012 Oct;5(5):698-704. doi: 10.1161/CIRCINTERVENTIONS.112.972463. Epub 2012 Oct 9.

2.

Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Uhry S, Bessereau J, Camoin-Jau L, Paganelli F, Bonello L.

Hosp Pract (1995). 2012 Apr;40(2):104-17. doi: 10.3810/hp.2012.04.976. Review.

PMID:
22615085
3.

Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.

Zhang L, Yang J, Zhu X, Wang X, Peng L, Li X, Cheng P, Yin T.

Thromb Res. 2015 Mar;135(3):449-58. doi: 10.1016/j.thromres.2014.12.007. Epub 2014 Dec 9. Review.

PMID:
25511576
4.

How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?

Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K; European Platelet Academy.

Thromb Haemost. 2015 Jan;113(1):37-52. doi: 10.1160/TH14-03-0238. Epub 2014 Sep 18. Review.

PMID:
25231675
5.

Response variability to P2Y12 receptor inhibitors: expectations and reality.

Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K; EPA (European Platelet Academy).

JACC Cardiovasc Interv. 2013 Nov;6(11):1111-28. doi: 10.1016/j.jcin.2013.06.011. Review.

6.

[Antiplatelet therapy in coronary heart disease. Some problems and achivements].

Gratsianskiĭ NA.

Kardiologiia. 2010;50(6):4-21. Review. Russian.

PMID:
20659022
7.

[Genetic variability in the efficacy of clopidogrel].

Kristensen KE, Rasmussen HB, Hansen PR.

Ugeskr Laeger. 2013 Mar 11;175(11):729-32. Review. Danish.

PMID:
23480885
8.

Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods.

Smock KJ, Saunders PJ, Rodgers GM, Johari V.

Am J Hematol. 2011 Dec;86(12):1032-4. doi: 10.1002/ajh.22112. Epub 2011 Aug 2. Review.

9.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

Price MJ, Tantry US, Gurbel PA.

Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Review.

PMID:
21546883
10.

Clinical impact of genetically determined platelet reactivity.

Laine M, Arméro S, Peyrol M, Sbragia P, Thuny F, Paganelli F, Bonello L.

J Cardiovasc Transl Res. 2013 Jun;6(3):398-403. doi: 10.1007/s12265-012-9421-4. Epub 2012 Nov 13. Review.

PMID:
23149816
11.

Role of phenotypic and genetic testing in managing clopidogrel therapy.

Chan NC, Eikelboom JW, Ginsberg JS, Lauw MN, Vanassche T, Weitz JI, Hirsh J.

Blood. 2014 Jul 31;124(5):689-99. doi: 10.1182/blood-2014-01-512723. Epub 2014 Jun 20. Review.

12.

Pharmacogenetics of clopidogrel.

O'Connor SA, Hulot JS, Silvain J, Cayla G, Montalescot G, Collet JP.

Curr Pharm Des. 2012;18(33):5309-27. Review.

PMID:
22724417
13.

Type 2 Diabetes and ADP Receptor Blocker Therapy.

Samoš M, Fedor M, Kovář F, Mokáň M, Bolek T, Galajda P, Kubisz P, Mokáň M.

J Diabetes Res. 2016;2016:6760710. doi: 10.1155/2016/6760710. Epub 2015 Dec 28. Review.

14.

Genetics of platelet inhibitor treatment.

Trenk D, Hochholzer W.

Br J Clin Pharmacol. 2014 Apr;77(4):642-53. doi: 10.1111/bcp.12230. Review.

15.

Metabolic differences of current thienopyridine antiplatelet agents.

Fareed J, Jeske W, Thethi I.

Expert Opin Drug Metab Toxicol. 2013 Mar;9(3):307-17. doi: 10.1517/17425255.2013.749238. Epub 2013 Jan 6. Review.

PMID:
23289968
17.

Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.

Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, Wei W.

Arch Cardiovasc Dis. 2013 Oct;106(10):517-27. doi: 10.1016/j.acvd.2013.06.055. Epub 2013 Sep 27. Review.

18.

Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists.

de Labriolle A, Doazan JP, Lemesle G, Bonello L.

Curr Cardiol Rep. 2011 Oct;13(5):439-50. doi: 10.1007/s11886-011-0208-z. Review.

PMID:
21800098
19.

Prasugrel.

Tello-Montoliu A, Tomasello SD, Angiolillo DJ.

Adv Cardiol. 2012;47:39-63. doi: 10.1159/000338044. Epub 2012 Aug 9. Review.

PMID:
22906902
20.

Pharmacogenomics of clopidogrel: evidence and perspectives.

Yin T, Miyata T.

Thromb Res. 2011 Oct;128(4):307-16. doi: 10.1016/j.thromres.2011.04.010. Epub 2011 May 18. Review.

PMID:
21592545

Supplemental Content

Support Center